Zurück
  • Short Talk
  • S-6-4

The vaccine candidate MVA-MERS-S against Middle East Respiratory Syndrome Coronavirus: safety and immunogenicity results from a randomized-controlled Phase Ib trial

Termin

Datum:
Zeit:
Redezeit:
Diskussionszeit:
Ort / Stream:
Lecture hall

Session

Tropical and Emerging Infections

Thema

  • Tropical and Emerging Infections

Mitwirkende

Dr. med. Anahita Fathi (Hamburg/ DE), Matthijs P. Raadsen (Rotterdam/ NL), Dr. Christine Dahlke (Hamburg/ DE), Anna Z. Mykytyn (Rotterdam/ NL), Leonie Mayer (Hamburg/ DE), Michael Klüver (Marburg/ DE; Giessen/ DE), Verena Krähling (Giessen/ DE; Marburg/ DE), Dr. Gesche Gerresheim (Giessen/ DE; Marburg/ DE), Dr. Svenja Hardtke (Hamburg/ DE), Anastasia Kelidou (Hamburg/ DE), Leonie M. Weskamm (Hamburg/ DE), Tamara Zoran (Hamburg/ DE), My Linh Ly (Hamburg/ DE), Monika Friedrich (Hamburg/ DE), Simon Schröder (Braunschweig/ DE), Klaus Schwamborn (Braunschweig/ DE), Thomas Hesterkamp (Braunschweig/ DE), Simone Kardinahl (Dessau/ DE), Prof. Dr. Asisa Volz (Hannover/ DE), Eric C.M. van Gorp (Rotterdam/ NL), Prof. Dr. Gerd Sutter (Munich/ DE), Prof. Dr. Stephan Becker (Giessen/ DE; Marburg/ DE), Prof. Dr. Bart Haagmans (Rotterdam/ NL), MVA-MERS-S-DF1 Study Group (N.A./ DE), Prof. Dr. Marylyn M. Addo (Hamburg/ DE)

  • © Conventus Congressmanagement & Marketing GmbH